These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19634640)

  • 21. [Current problems in the quality control of pharmaceutical preparations manufactured in pharmacies III. Investigation of theophilline containing suppositories].
    Takácsné NK; Sinkó B; Hang I; Kiss G; Dávid AZ; Horváth PE
    Acta Pharm Hung; 2007; 77(2):82-9. PubMed ID: 17933266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substandard and counterfeit medicines.
    Rassool GH
    J Adv Nurs; 2004 May; 46(3):338-9. PubMed ID: 15119344
    [No Abstract]   [Full Text] [Related]  

  • 23. [Evaluation of public awareness campaigns on counterfeit medicines in Cotonou, Benin].
    Abdoulaye I; Chastanier H; Azondekon A; Dansou A; Bruneton C
    Med Trop (Mars); 2006 Dec; 66(6):615-8. PubMed ID: 17286035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

  • 25. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction.
    Cohen JC; Mrazek M; Hawkins L
    Clin Pharmacol Ther; 2007 Mar; 81(3):445-9. PubMed ID: 17251983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Counterfeit drugs: defining the problem and finding solutions.
    Wertheimer AI; Santella TM
    Expert Opin Drug Saf; 2005 Jul; 4(4):619-22. PubMed ID: 16011440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugs, drugs--who has the drugs?
    Blair J
    J Healthc Prot Manage; 2012; 28(1):28-32. PubMed ID: 22423518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bad medicine in the market.
    Roger B; Boateng K
    World Hosp Health Serv; 2007; 43(3):17-21. PubMed ID: 18269104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Counterfeit drugs in Israel and worldwide. Part I: the extent of occurrence and impending threats].
    Tamir O; Friedman N; Furman-Assaf S; Marom E; Arieli M; Shemer J
    Harefuah; 2010 Jul; 149(7):466-9, 479. PubMed ID: 21465763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health risks of counterfeit pharmaceuticals.
    ten Ham M
    Drug Saf; 2003; 26(14):991-7. PubMed ID: 14583061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analytical challenges in drug counterfeiting and falsification-The NMR approach.
    Holzgrabe U; Malet-Martino M
    J Pharm Biomed Anal; 2011 Jun; 55(4):679-87. PubMed ID: 21232896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of drug authentication at the point of dispensing in Belgian and Greek community pharmacies.
    Simoens S
    Ann Pharmacother; 2009 Oct; 43(10):1701-6. PubMed ID: 19737993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report.
    WHO Expert Committee on Specifications for Pharmaceutical Preparations
    World Health Organ Tech Rep Ser; 2006; 937():1-461, back cover. PubMed ID: 16836287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the problem of counterfeit medications in the United Kingdom.
    Jackson G; Patel S; Khan S
    Int J Clin Pract; 2012 Mar; 66(3):241-50. PubMed ID: 22070229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of a reversed-phase LC method for analysing potentially counterfeit antimalarial medicines.
    Gaudiano MC; Antoniella E; Bertocchi P; Valvo L
    J Pharm Biomed Anal; 2006 Sep; 42(1):132-5. PubMed ID: 16517111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles for pharmacy in combatting counterfeit drugs.
    Ziance RJ
    J Am Pharm Assoc (2003); 2008; 48(4):e71-88; quiz e89-91. PubMed ID: 18653407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The usefulness of simple X-ray powder diffraction analysis for counterfeit control--the Viagra example.
    Maurin JK; Pluciński F; Mazurek AP; Fijałek Z
    J Pharm Biomed Anal; 2007 Mar; 43(4):1514-8. PubMed ID: 17127026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WHO tries to tackle problem of counterfeit medicines in Asia.
    Pincock S
    BMJ; 2003 Nov; 327(7424):1126. PubMed ID: 14615319
    [No Abstract]   [Full Text] [Related]  

  • 39. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perceptions and practices of pharmaceutical wholesalers surrounding counterfeit medicines in a developing country: a baseline survey.
    Khan MH; Akazawa M; Dararath E; Kiet HB; Sovannarith T; Nivanna N; Yoshida N; Kimura K
    BMC Health Serv Res; 2011 Nov; 11():306. PubMed ID: 22074046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.